Where Roivant Sciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Roivant Sciences (NASDAQ:ROIV) has received mixed analyst ratings in the past three months, with a total of 5 analysts offering their perspectives. The ratings include 2 bullish, 2 somewhat bullish, and 1 indifferent. The average 12-month price target for ROIV has been updated to $17.8, up from $14.50, indicating a 22.76% increase. Analysts from firms such as Truist Securities, Wolfe Research, HC Wainwright & Co., Piper Sandler, and B of A Securities have provided updates, with actions ranging from maintaining to raising and lowering their ratings and price targets. Roivant Sciences, a biopharmaceutical company, has shown impressive financial performance with a revenue growth rate of 117.8%, a net margin of 13721.55%, and ROE of 144.81%.
March 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roivant Sciences has received mixed analyst ratings but shows a positive trend with an updated average 12-month price target of $17.8, indicating a 22.76% increase from the previous target. The company's financial performance is strong, with significant revenue growth and profitability.
The mixed analyst ratings combined with the significant increase in the average price target suggest a positive outlook for ROIV in the short term. The company's impressive financial performance, including high revenue growth and profitability metrics, further supports this positive impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100